Dermira, Inc. (DERM) News
Filter DERM News Items
DERM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DERM News Highlights
- DERM's 30 day story count now stands at 5.
- Over the past 23 days, the trend for DERM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about DERM are CRVS and TOP.
Latest DERM News From Around the Web
Below are the latest news stories about JOURNEY MEDICAL CORP that investors may wish to consider to help them evaluate DERM as an investment opportunity.
Are You Looking for a Top Momentum Pick? Why Journey Medical Corporation (DERM) is a Great ChoiceDoes Journey Medical Corporation (DERM) have what it takes to be a top stock pick for momentum investors? Let's find out. |
What Makes Journey Medical Corporation (DERM) a Good Fit for 'Trend Investing'Journey Medical Corporation (DERM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
Is Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year. |
Journey Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call TranscriptJourney Medical Corporation (NASDAQ:DERM) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Ladies and gentlemen, thank you for standing by. Good afternoon. And welcome to Journey Medical’s Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Participants of this call are […] |
Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsCompany generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023, compared to a GAAP net loss of $10.1 million, or $0.57 per share basic and diluted for the third quarter of 2022 Received an upfront payment of $19.0 million upon entering into an exclusive license agreement with Maruho Co |
Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of DirectorsREDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointm |
Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023Company to host conference call to discuss financial results and provide a corporate update on November 7, 2023 at 4:30 p.m. ETSCOTTSDALE, Ariz., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third qua |
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)Study demonstrated systemic exposure of DFD-29 was significantly lower than that of Solodyn (105 mg) Data presented at 43rd Annual Fall Clinical Dermatology Conference New Drug Application submission to FDA for DFD-29 anticipated in the fourth quarter of 2023 SCOTTSDALE, Ariz., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription |
Journey Medical Gains 40%, Insider Trades Reap BenefitJourney Medical Corporation ( NASDAQ:DERM ) insiders who bought shares over the past year were rewarded handsomely last... |
Insider Buying: Journey Medical Corp's President & CEO Claude Maraoui Acquires 26,044 SharesOn September 6, 2023, Claude Maraoui, President & CEO of Journey Medical Corp (NASDAQ:DERM), made a significant insider purchase of 26,044 shares of the company's stock. |